Ocular Therapeutix (OCUL) EBITDA (2013 - 2026)

Ocular Therapeutix's EBITDA history runs 14 years deep, the most recent figure standing at -$93.3 million for Q1 2026.

• In Q1 2026, EBITDA fell 46.03% year-over-year to -$93.3 million; the TTM figure through Mar 2026 stood at -$299.4 million (down 46.73% YoY), while the FY2025 annual figure was -$270.0 million, down 57.19% from the prior year.
• EBITDA was -$93.3 million for Q1 2026 at Ocular Therapeutix, down from -$69.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$17.8 million in Q1 2022 to a low of -$93.3 million in Q1 2026.
• Historically, EBITDA has averaged -$41.0 million across 5 years, with a median of -$31.6 million in 2024.
• The sharpest annual moves came in 2022 and 2024: EBITDA grew 11.84% in 2022, then slumped 152.25% in 2024.
• A 5-year view of EBITDA shows it stood at -$19.4 million in 2022, then slipped by 3.56% to -$20.0 million in 2023, then plunged by 152.25% to -$50.6 million in 2024, then plunged by 37.93% to -$69.8 million in 2025, then tumbled by 33.8% to -$93.3 million in 2026.
• The last three EBITDA figures came in at -$93.3 million (Q1 2026), -$69.8 million (Q4 2025), and -$68.7 million (Q3 2025), per Business Quant data.